杜皮卢马布在治疗异性慢性鼻炎的长期有效性
Yasuhiro Tsunemi1, Tsuguhisa Nakayama1, Takashi Kashiwagi1
1Department of Otorhinolaryngology, Head and Neck Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan.
American journal of rhinology & allergy
|September 26, 2023
概括
杜皮卢马布治疗异性慢性鼻炎 (eCRS) 在短期内显著改善了鼻息肉和CT得分. 长期使用 (超过1年) 对eCRS患者的嗅觉恢复至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 异性慢性鼻炎 (eCRS) 是一种2型炎症状况,在手术后复发率高.
- 2020年在日本获得批准的杜皮卢马布 (Dupilumab) 为耐火性CRS提供了治疗选择.
- 关于dupilumab的长期疗效的数据有限,特别是在嗅觉功能恢复方面.
研究的目的:
- 为了评估dupilumab在手术后复发性CRS患者的长期临床疗效.
- 评估dupilumab在长时间内对鼻息肉评分,CT发现和嗅觉功能的影响.
主要方法:
- 在手术后用dupilumab治疗的20名eCRS患者的回顾性分析.
- 评估鼻息肉得分 (NPS),CT扫描得分,嗅觉功能 (T&T嗅觉计) 和嗅觉裂模糊在基线,短期 (平均值) 的评价. 5.1个月),以及长期的 (平均 18.3个月) 的时间.
主要成果:
- 在NPS和CT得分中观察到显著的短期改善 (P < .001,P = .008).
- CT评分显示长期持续改善,与短期 (P = .018) 和基线 (P = .008) 相比.
- 嗅觉功能和嗅觉裂模糊化仅在长期评估中显著改善 (P = .002,P = .006).
结论:
- 杜皮卢马布在长期使用时显示了NPS和CT得分的持续改善.
- 显著的嗅觉恢复和减少嗅觉裂模糊化需要超过一年的杜皮卢马布治疗.
- 症状/成像改善和嗅觉功能的恢复之间存在时间分离,突出显示需要延长治疗时间.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
474
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
474
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
01:19Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
01:26COPD: Management Using Bronchodilators and Corticosteroids
236
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
236